pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,728 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda recalls
therapy area
allOncology574Rare Disease284Immunology229Cardiology193Hematology159Pulmonology131Vaccines99
  • STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
    STAT · 2mo ago↗ source
  • STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
    A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
    STAT · 2mo ago↗ source
  • STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
    By doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
    STAT · 2mo ago
← prev
page 45 of 70
next →
22
fda press21
fda medwatch17
Psychiatry & CNS87
Ophthalmology86
Pain75
Endocrinology & Metabolism52
Dermatology51
↗ source
  • Akeso, Summit drug extends survival in closely watched lung cancer trial
    Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
    BioPharma Dive · 2mo ago↗ source
  • ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
    Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
    BioPharma Dive · 2mo ago↗ source
  • #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
    Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-F…
    Endpoints · 2mo ago↗ source
  • #ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
    CHICAGO — Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved ...
    Endpoints · 2mo ago↗ source
  • STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
    ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
    STAT · 2mo ago↗ source
  • STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
    Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
    STAT · 2mo ago↗ source
  • STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
    CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
    STAT · 2mo ago↗ source
  • Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more
    Welcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t already, check out Ma…
    Endpoints · 2mo ago↗ source
  • STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
    Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
    STAT · 2mo ago↗ source
  • STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
    You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…
    STAT · 2mo ago↗ source
  • At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
    Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
    BioPharma Dive · 2mo ago↗ source
  • Bristol Myers unveils data for one of its next-gen blood cancer drugs
    Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
    BioPharma Dive · 2mo ago↗ source
  • STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchers
    The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.
    STAT · 2mo ago↗ source
  • Next FDA user fee deal is under review at the White House
    The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sour…
    Endpoints · 2mo ago↗ source
  • Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
    Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings pres…
    Endpoints · 2mo ago↗ source
  • Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
    A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
    BioPharma Dive · 2mo ago↗ source
  • AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
    🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…
    Endpoints · 2mo ago↗ source
  • Replimune will again submit its melanoma drug for approval
    Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...
    Endpoints · 2mo ago↗ source
  • Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
    A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
    STAT · 2mo ago↗ source
  • Agios ends development of tebapivat in low-risk MDS following subpar results
    Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…
    Endpoints · 2mo ago↗ source
  • Allogene CEO to step down; Agios drug fails key test
    David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
    BioPharma Dive · 2mo ago↗ source
  • Can a chaotic FDA still deliver on faster drug development?
    As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep speedier drug approvals on track.
    BioPharma Dive · 2mo ago↗ source